Stock data
Immuneering Corporation (IMRX)
Immuneering Corporation (IMRX) reported net income of -US$56.02M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$59.38M | -US$56.02M | — |
| 2024 | — | — | -US$64.07M | -US$61.04M | — |
| 2023 | US$0.00M | US$0.00M | -US$58.41M | -US$53.47M | — |
| 2022 | US$0.32M | US$0.16M | -US$51.74M | -US$50.51M | — |
| 2021 | US$2.08M | US$0.93M | -US$33.89M | -US$33.54M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$17.27M | — |
| 2026-03-31 | — | -US$13.46M | — |
| 2025-12-31 | — | -US$11.58M | — |
| 2025-09-30 | — | -US$14.96M | — |
| 2025-06-30 | — | -US$14.43M | — |
| 2025-03-31 | — | -US$15.05M | — |
| 2024-12-31 | — | -US$18.05M | — |
| 2024-09-30 | — | -US$14.60M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.